Duchenne Muscular Dystrophy (DMD)

Sarepta Announces Revised Timeline for Eteplirsen FDA Application

Boys with Duchenne muscular dystrophy between the ages of seven and 16 are now being recruited to participate in a phase 3 clinical trial to evaluate the effectiveness and safety of eteplirsen in treating DMD.

DMD: Sarepta Updates Community on Eteplirsen, Other Compounds

First Drug for Duchenne Muscular Dystrophy Gets 'Conditional Approval' in Europe

DMD: Ataluren Receives Conditional Approval in Europe

PTC Therapeutics Receives Conditional Approval in the European Union for Translarna™ for the treatment of Nonsense Mutation Duchenne Muscular Dystrophy

DMD: ReveraGen Drug Will Move to Human Testing

International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug

DMD: Eteplirsen Data Still Encouraging at 144 Weeks

Sarepta Therapeutics Reports Long-Term Outcomes from Phase IIb Study of Eteplirsen

DMD: HT-100 Trial Has Reopened

Pages